Moderna Stock More Than Doubled in August. Is the Stock a Buy, a Hold, or a Sell?
The company may be on track to its next product.
Moderna (NASDAQ:MRNA) has experienced a remarkable surge in its stock price in August, more than doubling its value. The biotech company's innovative mRNA technology has proven its worth once again. This latest rally was sparked by the positive results of Moderna's personalized mRNA cancer vaccine in its first late-stage trial, conducted alongside Merck's Keytruda.
The stock experienced a 177% increase in one trading session, and by the end of August, it had risen by approximately 150%. The company's success in developing a game-changing advancement has once again led investors to rush in, driving the stock's value to new heights. However, like in the past, after such a significant surge, it remains to be seen if the good news can sustain the stock's gains. Investors are now questioning whether Moderna stock is a buy, a hold, or a sell.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
